How to Lose Weight After 40: Diet and NHS Help

How to lose weight after 40 is a question many people find themselves asking as the strategies that once worked begin to feel less effective. Age-related changes in metabolism, muscle mass and hormones mean that weight management at this life stage requires a more considered approach. This article explains why losing weight becomes harder after 40, which diet and exercise strategies are best supported by evidence, how hormonal changes such as the menopause and testosterone decline play a role, and what medical treatments are available through the NHS for those who need additional support.

Why is it harder to lose weight after 40?

Weight loss becomes harder after 40 primarily due to progressive muscle loss (sarcopenia), declining testosterone and growth hormone, and hormonal shifts that promote abdominal fat storage and reduce resting metabolic rate.

Losing weight after 40 becomes harder primarily because of age-related changes in metabolism, muscle mass and hormones that alter how the body stores and burns energy. From around the age of 30, adults lose muscle mass progressively with age, a process called sarcopenia. Because muscle tissue burns more calories at rest than fat tissue, a reduction in muscle mass lowers the basal metabolic rate, meaning the body requires fewer calories to maintain its current weight.

Hormonal shifts compound this effect. Testosterone and growth hormone begin to decline gradually from around the fourth decade of life in both men and women, influencing where fat is deposited and how efficiently it is mobilised. In women, the more pronounced decline in oestrogen occurs during the perimenopause and menopause, and is discussed further below. Many people in their 40s notice a shift towards central or abdominal fat accumulation, which carries a higher metabolic risk than fat stored elsewhere.

Lifestyle factors also play a role. Increased work and family responsibilities can reduce time for physical activity and disrupt sleep. Research suggests that poor sleep quality is associated with changes in appetite-regulating hormones, including elevated ghrelin and reduced leptin, which may make appetite harder to regulate, though the relationship is complex. Stress raises cortisol, which is associated with fat storage around the abdomen.

Understanding these mechanisms is important because it means that strategies that worked in your 20s, such as simply cutting calories for a few weeks, may be less effective in your 40s. A more structured, sustained approach that addresses muscle maintenance, sleep, stress and dietary quality is generally needed.

What diet changes actually work for weight loss in your 40s?

Prioritising protein, reducing ultra-processed foods and maintaining a moderate calorie deficit are the most evidence-supported dietary approaches for weight loss in your 40s.

A diet that prioritises protein intake, limits ultra-processed foods and maintains a modest calorie deficit is the approach most consistently supported by evidence for weight loss in people over 40. There is no single diet that works for everyone, but several principles are well established.

Prioritise protein. Adequate protein intake helps preserve muscle mass during weight loss and increases satiety. The British Dietetic Association and some expert groups suggest higher protein intakes may be beneficial for older adults and those losing weight; a registered dietitian can advise on an appropriate target for your individual circumstances. Good sources include lean meat, fish, eggs, dairy, legumes and tofu. Note: people with chronic kidney disease should seek advice from their GP or dietitian before substantially increasing protein intake, as higher intakes may not be appropriate.

Reduce ultra-processed foods. Foods high in refined carbohydrates, added sugars and saturated fats tend to be calorie-dense and less filling. Replacing them with whole grains, vegetables, fruit and healthy fats, in line with the NHS Eatwell Guide, supports both weight management and cardiovascular health, which becomes increasingly important after 40.

Consider meal timing. Some research suggests that eating the majority of calories earlier in the day and avoiding late-night eating may support metabolic health, though the evidence is mixed and this should be adapted to individual circumstances rather than treated as a substitute for overall dietary quality.

Avoid extreme restriction. Very low-calorie diets can accelerate muscle loss and are difficult to sustain. A moderate calorie deficit is generally recommended as a sustainable starting point; the NHS Weight Loss Plan typically suggests a deficit of around 600 calories per day, though the right level for you will depend on your starting point and should be discussed with a healthcare professional.^[1]

Keeping a food diary, even briefly, can help identify patterns and hidden calorie sources. Consulting a registered dietitian can provide personalised guidance, particularly if you have an existing health condition such as type 2 diabetes or cardiovascular disease.

How much exercise do you need to lose weight after 40?

NHS guidelines recommend at least 150 minutes of moderate aerobic activity per week plus muscle-strengthening exercise on two or more days, with strength training particularly important after 40 to counter muscle loss.

Adults over 40 are recommended by NHS and UK Chief Medical Officers' guidelines to aim for at least 150 minutes of moderate-intensity aerobic activity per week, or 75 minutes of vigorous-intensity activity, or an equivalent combination of both, alongside muscle-strengthening activities on two or more days per week. This combination is particularly important for weight management at this life stage. Moderate-intensity activity includes brisk walking, cycling, swimming and dancing, where you can talk but not sing comfortably.

Strength training deserves particular emphasis after 40 because it directly counteracts the age-related loss of muscle mass described above. Resistance exercises, whether using weights, resistance bands or bodyweight, help maintain and rebuild muscle, which in turn supports a higher resting metabolic rate. Even two sessions per week of 20 to 30 minutes can produce meaningful benefits over time.

For those new to exercise or returning after a break, starting gradually and building up over several weeks reduces the risk of injury. Low-impact options such as swimming, cycling or yoga are particularly suitable if joint pain is a concern, which becomes more common in midlife. If you have significant health conditions or experience new or concerning symptoms during exercise, speak to your GP before starting or significantly increasing activity.

Practical tips for staying active after 40:

• Break activity into shorter sessions of 10 minutes or more if a full 30-minute block is difficult to fit in

• Incorporate incidental movement such as taking stairs, walking to meetings or gardening

• Consider working with a qualified personal trainer, at least initially, to learn safe resistance training technique

• Prioritise consistency over intensity, as regular moderate activity produces better long-term outcomes than sporadic intense sessions

Exercise alone rarely produces large amounts of weight loss without dietary changes, but it is essential for maintaining weight loss and for overall health.

Does the menopause or testosterone decline affect your weight?

The menopause promotes a shift from subcutaneous to visceral abdominal fat due to declining oestrogen; in men, gradual testosterone decline from around 40 reduces muscle mass and increases body fat.

The menopause directly contributes to weight gain and changes in fat distribution in women, primarily through the decline in oestrogen that occurs during the perimenopause and after the final menstrual period. Oestrogen plays a role in regulating fat storage, and its reduction is associated with a shift from subcutaneous fat (stored under the skin) to visceral fat (stored around the abdominal organs). Research and clinical guidance from the British Menopause Society suggest this redistribution can occur even in the absence of significant changes in total calorie intake, though overall energy balance remains important.

The perimenopause typically begins in the mid-40s and can last several years before the menopause itself, which in the UK occurs at an average age of 51. Symptoms such as poor sleep, low mood and fatigue, which are common during this transition, can further disrupt appetite regulation and reduce motivation for physical activity.

Menopause hormone therapy (MHT, previously called HRT) is not associated with weight gain according to current evidence, and some research suggests it may help reduce the accumulation of visceral fat. Women concerned about menopausal symptoms and their effect on weight should discuss MHT with their GP, as it may be appropriate for many women without contraindications.

In men, age-related testosterone decline (sometimes called testosterone deficiency or late-onset hypogonadism) occurs gradually from around the age of 40 onwards. Lower testosterone is associated with reduced muscle mass, increased body fat and lower energy levels. This is a gradual process rather than a defined event, and many symptoms overlap with other conditions. Men who are concerned should speak to their GP; assessment typically includes measurement of morning testosterone on at least two occasions alongside evaluation of other possible causes, before any treatment is considered.

When should you talk to your GP about weight loss support?

Speak to your GP if your BMI is at or above the relevant threshold for your ethnic background, if you have a weight-related health condition, or if sustained lifestyle changes have not produced results.

You should talk to your GP about weight loss support if you have a body mass index (BMI) of 30 or above, or a BMI of 27.5 or above if you are from a South Asian, Chinese, Black African or Black Caribbean background, as these thresholds are associated with increased health risks and may make you eligible for structured support. You should also seek advice if you have a weight-related health condition such as type 2 diabetes, high blood pressure, sleep apnoea or joint problems, or if you have been unable to achieve or maintain weight loss through lifestyle changes alone.

Your GP can assess whether an underlying medical condition is contributing to weight gain. Hypothyroidism (an underactive thyroid), polycystic ovary syndrome (PCOS) and certain medications, including some antidepressants, antipsychotics and corticosteroids, can all promote weight gain and may need to be addressed as part of a broader management plan.

GPs can also refer patients to NHS weight management services, which range from brief advice and digital programmes to specialist tier 3 and tier 4 services for people with complex needs. Referral criteria vary between Integrated Care Boards (ICBs) in England, and devolved arrangements apply in Scotland, Wales and Northern Ireland, so local availability differs across the UK.

Reasons to contact your GP about weight:

• BMI at or above the relevant threshold for your ethnic background

• Unexplained or unintentional weight loss, which should always be assessed promptly

• Unexplained or rapid weight gain

• Weight-related health conditions that are worsening

• Difficulty losing weight despite sustained lifestyle changes

• Concerns about the effect of medications on your weight

If you are unsure whether your symptoms warrant a GP appointment, NHS 111 can provide guidance.

What medical treatments are available for weight loss on the NHS?

NHS weight management medicines include orlistat, injectable semaglutide (Wegovy), liraglutide (Saxenda), tirzepatide (Mounjaro) and oral semaglutide, with bariatric surgery available for those meeting specific BMI criteria.

Several medical treatments for weight loss are available in the UK, including licensed medicines and bariatric surgery, though access through the NHS depends on clinical eligibility and local ICB commissioning decisions. NICE technology appraisals have recommended certain medicines for use within NHS specialist weight management services, but NHS availability does not follow automatically from a NICE recommendation, and criteria vary by area.

Licensed weight management medicines in the UK include:

• Orlistat (Xenical, Alli): A lipase inhibitor that reduces dietary fat absorption. It is available on NHS prescription and, at a lower dose, over the counter. It is typically recommended alongside a calorie-reduced diet.

• Semaglutide injection (Wegovy): A GLP-1 receptor agonist licensed for chronic weight management, given as a weekly subcutaneous injection. The licensed dose range includes strengths up to 2.4 mg weekly, with a higher 7.2 mg strength also authorised by the MHRA. NICE has recommended it within specialist services for eligible patients.

• Oral semaglutide (Wegovy 25 mg tablets): An oral formulation of semaglutide for weight management, approved by the MHRA in June 2026. This is a separate product from injectable Wegovy and from Rybelsus, with its own licensed posology. NHS access and commissioning arrangements are still being established.

• Liraglutide (Saxenda): Another GLP-1 receptor agonist, given as a daily injection, licensed for weight management.

• Tirzepatide (Mounjaro): A dual GIP and GLP-1 receptor agonist authorised by the MHRA for both type 2 diabetes and chronic weight management. NICE has recommended it within specialist NHS weight management services for eligible patients. Mounjaro is available as a multiple-dose KwikPen, with each pen containing four weekly doses. For those exploring private options, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a medicine such as Mounjaro may be considered if it is clinically appropriate.

• Orforglipron (Foundayo): An oral GLP-1 receptor agonist that has received a UK marketing authorisation.^[16] NHS commissioning arrangements are still being established; speak to your GP or a specialist for the most current information on access.

Bariatric surgery, including gastric bypass and sleeve gastrectomy, is available on the NHS for people meeting specific criteria, typically a BMI of 40 or above, or 35 or above with a significant obesity-related condition.^[18]

Important safety information for weight management medicines:

Weight management medicines are not suitable for use during pregnancy, when planning a pregnancy or while breastfeeding. Women of childbearing potential should discuss contraception with their prescriber before starting treatment.

GLP-1 receptor agonists commonly cause nausea, vomiting and gastrointestinal discomfort, particularly during dose escalation. Pancreatitis has been reported with this class of medicine, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome. If you develop severe and persistent abdominal pain, seek urgent medical attention by calling NHS 111 or, if symptoms are severe, attending an emergency department or calling 999.

Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Calories and weight loss – Better Health.
2. UK Chief Medical Officers' physical activity guidelines.
3. Physical activity guidelines for adults aged 19 to 64.
4. Understanding weight gain at menopause. Climacteric. 2012..
5. Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes. Obesity (Silver Spring). 2014..
6. Menopause and perimenopause.
7. Overweight and obesity management (NG246) – Identifying and assessing overweight, obesity and central adiposity.
8. Overweight and obesity in adults.
9. Orlistat – BNF.
10. Orlistat: a medicine to treat obesity.
11. Wegovy (semaglutide) – Product Information (EPAR).
12. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity.
13. First GLP-1 tablet for weight loss approved in the UK.
14. Tirzepatide for managing overweight and obesity (TA1026).
15. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
16. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
17. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
18. Overweight and obesity management (NG246) – Medicines and surgery.
19. A single night of sleep deprivation increases ghrelin levels. J Sleep Res. 2008..
20. Effect of sleep duration on dietary intake, desire to eat, measures of food intake and metabolic hormones: a systematic review of clinical trials. Clin Nutr ESPEN. 2021..

Frequently Asked Questions